Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar;18(3):10.
doi: 10.1007/s11908-016-0516-y.

Relevant Cytokines in the Management of Community-Acquired Pneumonia

Adrian Rendon  1 , Erick J Rendon-Ramirez  2 , Adrian G Rosas-Taraco  3
Affiliations

Relevant Cytokines in the Management of Community-Acquired Pneumonia

Adrian Rendon et al. Curr Infect Dis Rep. 2016 Mar.

Abstract

Community-acquired pneumonia (CAP) is the leading cause of infectious death in the world. Immune dysregulation during acute lung infection plays a role in lung injury and the systemic inflammatory response. Cytokines seem to be major players in severe lung infection cases. Here, we present a review of published papers in the last 3 years regarding this topic. The cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as CURB65 or SOFA. Treatment focused in the cytokine environment is an interesting area that could impact the prognosis of CAP. Some of the agents that have been studied as co-adjuvant therapy are corticosteroids, macrolides, and linezolid, but anyone of those have shown a clear or proven efficacy or have been recommended as a part of the standard of care for CAP. More studies designed to define the role of immunomodulatory agents, such as co-adjuvant therapy in pneumonia, are needed.

Keywords: Community-acquired pneumonia (CAP); Cytokines; Immune regulation; Management; Therapy.

PubMed Disclaimer

Conflict of interest statement

Drs Rendon, Rendon-Ramirez, and Rosas-Taraco declare no conflicts of interests.

Figures

Fig. 1
Fig. 1
Representation of inflammatory response in CAP and potential points to use anti-cytokine treatment
See this image and copyright information in PMC

References

    1. Johnstone J, Mandell L. Guidelines and quality measures: do they improve outcomes of patients with community-acquired pneumonia? Infect Dis Clin North Am. 2013;27(1):71–86. doi: 10.1016/j.idc.2012.11.001. - DOI - PubMed
    1. Wunderink RG, Waterer GW. Clinical practice. Community-acquired pneumonia. N Engl J Med. 2014;370(6):543–51. doi: 10.1056/NEJMcp1214869. - DOI - PubMed
    1. Sligl WI, Marrie TJ. Severe community-acquired pneumonia. Crit Care Clin. 2013;29(3):563–601. doi: 10.1016/j.ccc.2013.03.009. - DOI - PMC - PubMed
    1. Fernandez-Botran R, Uriarte SM, Arnold FW, et al. Contrasting inflammatory responses in severe and non-severe community-acquired pneumonia. Inflammation. 2014;37(4):1158–66. doi: 10.1007/s10753-014-9840-2. - DOI - PMC - PubMed
    1. Menendez R, Sahuquillo-Arce JM, Reyes S, et al. Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. Chest. 2012;141(6):1537–45. doi: 10.1378/chest.11-1446. - DOI - PMC - PubMed

LinkOut - more resources